Follow on Google News News By Tag * Biosimilar * Patent * Resistors * Biologic * Expiries * Developing * Pathways * Biologics * Eopean * Somatropin * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | New Market Report Now Available: Pharmaceutical Key Trends 2011 - Biosimilar Market OverviewRecently published research from Datamonitor, "Pharmaceutical Key Trends 2011 - Biosimilar Market Overview", is now available at Fast Market Research
In 2009, the combined biosimilars market size for the US and five major eopean markets was $150m. With more than 30 branded biologics with sales of $51bn set to lose patent exclusivity between 2011 and 2015, Datamonitor forecasts that the global biosimilar market will grow from $243m in 2010 to $3.7bn in 2015. Features and benefits * Overview of the biosimilar market, with biosimilar definitions in the US, EU and Japan, plus historical and forecast biosimilar sales out to 2015. * Insight into the key drivers and resistors to biosimilar uptake in the developed and emerging markets. * Assesses key factors determining successful biosimilar market access, and examines the major biosimilar players and the strategies they implement. * Analyses biosimilar uptake in the five main eopean markets and provides insight into the future opportunities for biosimilar players. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Highlights Due to their complexity, cost, and development risks, biosimilar production and commercialization in developed markets is concentrated among only a handful of pharma companies, all of which are established generics players. Despite the introduction of approval pathways in the US, EU, and Japan, the growing use of biologics, and the need for more cost-effective treatments, all of which help drive biosimilar uptake, there remain a large number of barriers to uptake. There are relatively few factors which limit the growth of the biosimilar industry in the developing markets, although the introduction of biosimilar pathways will restrict market access to many domestic biosimilar players, while low purchasing power and a high proportion of out-of-pocket expenditure, coupled with brand loyalty, limit access. Your key questions answered * Evaluate the evolving regulatory environment in the US, EU and Japan, and how this impacts biosimilar market access and uptake. * Gain insight into the deal types among branded, generic and biosimilars players to either enter or bolster their position in the biosimilars market. * Identify which branded biologics are facing patent expiry and provide significant opportunities for biosimilar developers. Report Table of Contents: Executive Summary Introduction Strategic scoping and focus Key findings Related reports Upcoming related reports 2. GLOBAL BIOSIMILAR MARKET SIZE Biosimilar definitions Biosimilar sales in Biologic sales exposed to potential biosimilar competition during 2011- Forecast biosimilar sales, 2010- Profitability of biosimilars versus branded biologics and generics 3. DRIVERS AND RESISTORS TO BIOSIMILAR UPTAKE Drivers and resistors to biosimilar uptake in the developed markets Drivers of biosimilar uptake in developed markets Neutral factors impacting biosimilar uptake in developed markets Resistors to biosimilar uptake in developed markets Drivers and resistors to biosimilar uptake in Brazil, Russia, India, and China Drivers of biosimilar uptake in emerging markets Resistors impacting biosimilar uptake in emerging markets 4. BIOSIMILAR MARKET ACCESS Key factors in determining the success of biosimilar market access Biosimilar development timeline Biosimilar development costs Pros and cons of developing and manufacturing biosimilars in developing markets Biosimilar approval pathways Biosimilar producers face a challenging patent environment Biosimilar pricing in developed markets Partnerships help drive growth of the biosimilars industry 5. KEY BIOSIMILAR PLAYERS Key biosimilar players in the developed and emerging markets Key biosimilar players in the developed markets Key players in the emerging markets 6. BIOSIMILARS BY GEOGRAPHIC MARKET Biosimilar launches US biosimilars market Biosimilars in the five major EU markets Japanese biosimilars market Australian biosimilars market BRIC biosimilars market 7. BIOSIMILAR UPTAKE Uptake of biosimilar somatropin, filgrastim and epoetin Biosimilar somatropin Biosimilar filgrastim Biosimilar epoetin 8. OPPORTUNITIES FOR THE BIOSIMILAR INDUSTRY Branded biologic patent expiries present opportunities for the biosimilar industry Biologic patent expiries in the US Biologic patent expiries in the five major EU markets Biologic patent expiries in Japan Biosimilars in development internationally Biosimilar MAbs and second-generation biosimilars offer the greatest commercial potential 9. BIBLIOGRAPHY Publications and online articles APPENDIX Exchange rates used in this report About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|